Study Finds Delayed Treatment Acceptable for MCL Patients

by: cancercompass

New research says a "watch and wait" approach to treating asymptomatic patients with mantel-cell lymphoma (MCL) is an acceptable management approach according to a recent study published by the Journal of Clinical Oncology.

Currently, there isn't a standardized treatment for MCL, other than doctors typically begin treatment immediately after diagnosis, according to the study abstract. Researchers from Weill Cornell Medical College and New York Presbyterian Hospital wanted to analyze the outcome of deferring the initial therapy, as there currently is not any documented research done on deferring initial treatment.

Investigators reviewed hospital and research charts for 97 patients diagnosed between 1997 and 2007 where the first date of treatment was known.  

Overall study findings suggested those patients observed prior to treatment, three months before initial systematic therapy was done, had better statistical odds of survival than the group treated right away, suggesting that the "watch and wait" method is an acceptable management approach.

However, researchers noted that time to treatment didn't predict overall survival in a multivariate analysis.